title: Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).
abstract: Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds.
authors.affiliation: Cardiovascular Department, Ferrarotto Hospital, University of Catania, Italy. dcapodanno@gmail.com
authors.forename: Davide
authors.initials: D
authors.lastname: Capodanno
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giacchi
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors*; D000931:Antidotes / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D003029:Coagulants / Q000627:therapeutic use*; D015195:Drug Design; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D010330:Patents as Topic
chemical_list: D000925:Anticoagulants; D000931:Antidotes; D003029:Coagulants